BAY 1436032Alternative Names: BAY1436032
Latest Information Update: 05 Jul 2016
At a glance
- Originator Bayer
- Class Antineoplastics
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 May 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT02746081)
- 08 Apr 2016 Preclinical trials in Solid tumours in Germany (PO) before April 2016